MEASLES & THE MMR VACCINE: RECOMMENDATIONS AROUND PREGNANCY, INCLUDING THE PERICONCEPTION AND POSTPARTUM PERIODS

Obstetric Consensus Statement

Alisa Kachikis, MD
Elizabeth Oler, MD
Raj Swati Shree, MD
Kristina Adams Waldorf, MD
Jane Hitti, MD MPH
Linda Eckert, MD

Revised April 2019
MEASLES & THE MMR VACCINE: RECOMMENDATIONS AROUND PREGNANCY, INCLUDING THE PERICONCEPTION AND POSTPARTUM PERIODS

RATIONALE
Measles, also known as rubeola, is a highly contagious airborne viral illness that infects approximately nine out of ten exposed susceptible individuals. Measles infection was common until the measles, mumps, and rubella (MMR) vaccine was licensed in 1963 and became part of the routine immunization schedule. By 2000, measles was essentially eliminated from the United States. In the last decade, however, vaccination rates have waned and the incidence of measles has again risen, with one of the most recent outbreaks in the Pacific Northwest. The majority of those affected are unvaccinated, indicating that undervaccination is a risk factor for susceptibility to measles infection.

What we know about measles
- The incubation period is 7-21 days; an infected individual is contagious from 4 days before until 4 days after the appearance of a rash. However, immunocompromised individuals may not develop a rash.
- It is transmitted via direct contact from person to person with respiratory droplets or airborne spread. The measles virus may remain airborne and infectious for up to two hours.
- Commonly reported complications include pneumonia, otitis media, and diarrhea.
- Two doses of the MMR vaccine series are 97% effective at preventing measles infection.
- An estimated 92-95% of individuals in a community must be immune to prevent ongoing transmission.
- Encephalitis, hearing loss, and death are very rare complications; however, these occur more commonly in infants, young children, and immunocompromised individuals.

IN PREGNANCY
Pregnant women and young children are among the populations at highest risk for complications. Measles infection in pregnant women is associated with increased risk of hospitalization and pneumonia. Measles infection during pregnancy is also associated with significant risk to the fetus, including miscarriage, stillbirth, low birth weight, and an elevated risk for preterm delivery. Infants born during an active maternal measles infection are at risk for congenital measles. Prior to the introduction of intravenous and intramuscular immunoglobulin therapy (IGIV and IGIM), congenital measles infection had high neonatal mortality rates. While most women have immunity to measles due to prior MMR vaccination, given risks associated with measles in pregnancy, possible infection or exposure to measles should be carefully and expediently investigated. Pregnant women with exposure but without immunity to measles may be eligible for IVIG treatment (see algorithm below). Live vaccines, such as MMR, are not recommended during pregnancy due to theoretical risks to the mother and fetus; however adverse effects on fetuses when live vaccines are inadvertently administered during pregnancy have not been found. In women at low risk for contracting measles, a documented history of one prior MMR vaccine is sufficient to confirm immunity. See algorithm below for guidance in managing high risk pregnant patients – those living in, or traveling to, areas with an active outbreak.
IN THE PERICONCEPTION PERIOD

Women of reproductive age and those contemplating conception should assess their measles immune status with their primary health provider prior to pregnancy (see algorithm below). After receiving the MMR vaccine, women should wait 4 weeks prior to attempting conception given theoretical risks to the fetus with live vaccines; however inadvertent MMR vaccination in the periconception period or in early pregnancy should not be considered an indication for termination of pregnancy.

IN THE POSTPARTUM PERIOD

Women who are found to be non-immune to measles or rubella should receive the MMR vaccine immediately after delivery. Breastfeeding has not been shown to affect the immune response to MMR. MMR vaccine is safe in breastfeeding mothers and has not been shown to have adverse effects in neonates. While breast milk transfer of measles protective maternal antibodies to the infant has not been well studied, maternal antibodies have been shown to be protective for the infant in other viral illnesses such as influenza.

ASSESSING IMMUNITY

Given risks associated with measles in pregnancy, possible infection or exposure to measles should be carefully and expeditiously investigated, and reproductive health providers should follow guidance by local health departments in areas of active outbreak. In these regions, it is imperative to assess immunity at the first prenatal visit (see algorithm). In the general population, including pregnant women, documentation of one dose of MMR is sufficient to assume immunity to measles. High-risk individuals, such as health-care personnel, students at post-high school institutions, and international travelers, should have two doses of MMR documented as evidence for presumptive immunity (see algorithm). If the patient has two doses of the MMR vaccine documented and presence of a positive rubella titer, immunity to measles is likely; in one study of 262 pregnant women in Canada, measles susceptibility was present in only 0.8% of rubella seropositive women, when tested via gold-standard plaque reduction neutralization test (PRNT). Several studies have shown lower correlation between rubella and measles immunity, however these studies utilized standard enzyme-linked immunosorbent assay (ELISA) tests which have significantly lower sensitivity than PRNT.

It is important to note that ELISA is the only test available in commercial laboratories. Although PRNT is the gold standard assay, it is more labor intensive and expensive, and is performed only in specialized laboratories such as those at the Centers for Disease Control and Prevention (CDC). The ELISA is less sensitive than the PRNT and negative results in particular should be interpreted with caution. One study in the UK correlating ELISA with PRNT revealed automated ELISA sensitivity and manual ELISA sensitivity, relative to PRNT, of 42% and 72%, respectively. Specificity for the automated and manual ELISA tests, however, was 100% and 97% respectively. These results suggest that a negative ELISA is ideally sent for PRNT testing for confirmation of susceptibility. Any positive immunoglobulin (IgG) result or titer by ELISA confirms immunity and no further testing is necessary.
Possible measles exposure?1,3
Exposure to individuals with measles or travel to areas with local epidemics (see below)?

Yes
Assess measles immunity (see below)
Meets criteria for presumptive evidence of immunity

No
Alert local health department

Pregnant?

Yes
Close monitoring Consult Maternal-Fetal Medicine/Perinatology Offer post-exposure prophylaxis with IVIG within 6 days of exposure (recommended dose 400 mg/kg)

No
Offer post-exposure prophylaxis with MMR vaccine (ideally within 72 hours of exposure)

Symptoms concerning for measles infection?2
Factors concerning for measles infection?

Yes
Test for measles IgM and RNA via RT-PCR in serum, throat and nasopharyngeal swabs, and urine

See: https://www.cdc.gov/measles/lab-tools/rt-pcr.html

No
Evaluate other possible sources of respiratory illness; treat symptoms; monitor with close follow up

Pregnant?

Yes
Close monitoring Precautions: airborne and standard Evaluation of pulmonary status Consult Maternal-Fetal Medicine/Perinatology Consult Infectious Disease specialist

No
Alert local health department immediately (24/7) while the individual is present prior to discharge from health facility

Assessing measles immunity1,3
Acceptable presumptive evidence of immunity to measles, if one of the following is true:

- Documentation (not only verbal report) of vaccination with at least 1 dose* of live measles virus containing vaccine (i.e. MMR)
- Laboratory evidence of immunity via measles-specific IgG antibody
- Laboratory confirmation of disease (gold standard)
- Born before 1957

Tests positive

Yes
Pregnant?

Yes
Offer post-exposure prophylaxis with MMR vaccine (ideally within 72 hours of exposure)

No
Considered immune

No
Considered non-immune

Tests negative

Yes
Pregnant?

Yes
Alert local health department immediately (24/7) while the individual is present prior to discharge from health facility

No
Close monitoring Precautions: airborne and standard Evaluation of pulmonary status Consult Maternal-Fetal Medicine/Perinatology Consult Infectious Disease specialist

THINKING ABOUT TRAVELING?

Refer to the following website for updated news and locations of measles outbreaks:
https://www.cdc.gov/measles/cases-outbreaks.html

---

*In the general population, including pregnant women, documentation of one dose of MMR is sufficient to assume immunity to measles. High-risk individuals, such as health-care personnel, students at post-high school institutions, and international travelers, should have two doses of MMR documented as evidence for presumptive immunity.1

**PRNT assays are labor- and time-intensive, and may not be readily available. In addition, PRNT assays may not result for days or weeks. Therefore, immunity testing availability and algorithms should be discussed with the local health department.

Abbreviations: ELISA, enzyme-linked immunosorbent assay; IVIG, intravenous immunoglobulin; MMR, measles mumps and rubella vaccine; PRNT, plaque reduction neutralization test; RT-PCR, real-time polymerase chain reaction.
REFERENCES


CITATION